Navigation Links
Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
Date:9/25/2008

Data Validates Neuroprotective Effect of Quark's New RNAi Product on Dying Retinal Ganglion Cells, a Cause of Blindness in Glaucoma

FREMONT, Calif., Sept. 25 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced QPI-1007 as the Company's first siRNA drug candidate based on its own intellectual property for a host of novel structures having freedom to operate in the siRNA IP space. QPI-1007, which is currently being evaluated in advanced IND enabling preclinical studies as a neuroprotective agent for eye diseases, is the first drug candidate to utilize a novel siRNA structure developed by Quark free of third party IP. The Company is utilizing its proprietary structures and intellectual property to develop additional RNAi drug candidates in its robust pipeline.

Quark has completed studies with QPI-1007 in different animal models of acute and severe optic nerve injury. In collaboration with Prof. Ann Logan of the Division of Medical Sciences, Department of Medicine, University of Birmingham, UK, Quark examined QPI-1007's effectiveness in a model of retinal ganglion cell (RGC) death by optic nerve crush (ONC). In a second study of QPI-1007 in collaboration with Prof. Adriana Di Polo of the Department of Pathology and Cell Biology, Universite de Montreal, its effectiveness was examined in a model of RGC death induced by axotomy of the optic nerve. QPI-1007 displayed neuroprotective activity towards RGCs. It significantly protected retinal neurons against delayed degeneration and reduced injury induced RGC death in vivo, the hallmarks of glaucoma and acute injuries such as ischemic optic neuropathy.

Dr. Daniel Zurr, Quark's Chief Executive Officer, stated, "With more RNAi products in human trials than any other company in the industry, Quark has proven its ability to advance siRNA products from discovery to the clinic.
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  In any given hospital ... 25 patients has at least one hospital-acquired infection, according ... more, many of these infections prove fatal. And as ... alarming number of patient deaths per year, infection control ... Consequently, a stronger emphasis is being ...
(Date:7/24/2014)... DALLAS , July 24, 2014 /PRNewswire-iReach/ -- ... days once order is placed. Photo ... is a professional and in-depth market survey on ... firstly reviews the basic information of Hemodialysis Machine ... report then explores global and China,s top manufacturers ...
(Date:7/24/2014)... -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR ) today ... 2014. Three Months Ended 06/30/14Three Months Ended 06/30/13 ,  Percentage ... 51% Non-GAAP Net Sales , $278.8 Million , $196.1 ... , $1.12 , 37% Non-GAAP Diluted ... 37%  Six Months Ended 06/30/14Six Months Ended 06/30/13 , ...
Breaking Medicine Technology:Employees, Equipment and the Environment: Top Infection Prevention Focuses in Hospitals 2Employees, Equipment and the Environment: Top Infection Prevention Focuses in Hospitals 3Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 2Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 3Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 4Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 5Questcor Reports Record Second Quarter Financial Results 2Questcor Reports Record Second Quarter Financial Results 3Questcor Reports Record Second Quarter Financial Results 4Questcor Reports Record Second Quarter Financial Results 5Questcor Reports Record Second Quarter Financial Results 6Questcor Reports Record Second Quarter Financial Results 7Questcor Reports Record Second Quarter Financial Results 8Questcor Reports Record Second Quarter Financial Results 9Questcor Reports Record Second Quarter Financial Results 10Questcor Reports Record Second Quarter Financial Results 11Questcor Reports Record Second Quarter Financial Results 12Questcor Reports Record Second Quarter Financial Results 13Questcor Reports Record Second Quarter Financial Results 14Questcor Reports Record Second Quarter Financial Results 15Questcor Reports Record Second Quarter Financial Results 16Questcor Reports Record Second Quarter Financial Results 17Questcor Reports Record Second Quarter Financial Results 18Questcor Reports Record Second Quarter Financial Results 19Questcor Reports Record Second Quarter Financial Results 20Questcor Reports Record Second Quarter Financial Results 21Questcor Reports Record Second Quarter Financial Results 22Questcor Reports Record Second Quarter Financial Results 23Questcor Reports Record Second Quarter Financial Results 24Questcor Reports Record Second Quarter Financial Results 25Questcor Reports Record Second Quarter Financial Results 26Questcor Reports Record Second Quarter Financial Results 27Questcor Reports Record Second Quarter Financial Results 28
... WaferGen Biosystems, Inc. (OTC Bulletin Board: WGBS ... today announced that it has appointed world-renowned clinical genomics ... Scientific Advisory Board.   Dr. Chinnaiyan is ... the clinic to choose appropriate therapies for cancer patients. ...
... SAN DIEGO, Jan. 19, 2011 ADVENTRX Pharmaceuticals, Inc. (NYSE ... Food and Drug Administration (FDA) has established a Prescription Drug ... the review of the Exelbine (ANX-530) New Drug Application (NDA). ... that the application is sufficiently complete to permit a substantive ...
Cached Medicine Technology:WaferGen Appoints World-Renowned Clinical Genomics Cancer Researcher Dr. Arul M. Chinnaiyan to Scientific Advisory Board 2WaferGen Appoints World-Renowned Clinical Genomics Cancer Researcher Dr. Arul M. Chinnaiyan to Scientific Advisory Board 3WaferGen Appoints World-Renowned Clinical Genomics Cancer Researcher Dr. Arul M. Chinnaiyan to Scientific Advisory Board 4ADVENTRX Pharmaceuticals Receives PDUFA Date for Exelbine™ NDA 2ADVENTRX Pharmaceuticals Receives PDUFA Date for Exelbine™ NDA 3
(Date:7/24/2014)... Journal of Oral Implantology —Success of a ... the alveolar ridge—an indication of the amount of bone ... exist, each with their own advantages, to determine bone ... highlighted as a strategy for treating horizontally collapsed alveolar ... comparison of two commonly used techniques , the ...
(Date:7/24/2014)... The U.S. Preventive Services Task Force recently ... at high risk for cancer, but a potential ... have positive results on the screening test, only ... policymakers have expressed concern that this high false-positive ... A new study of National Lung Screening Trial ...
(Date:7/24/2014)... Voted one of the most reliable online dress ... on providing its new and old customers with the ... has announced its new collection of high end wedding ... according to the latest fashion trends. Additionally, they are ... , As a matter of fact, high end special ...
(Date:7/24/2014)... 2014 Four Seasons Resort Maui ... its $3 million renovation of the famed Maile suite ... suites, just in time to welcome summer guests vacationing ... direction from the internationally-acclaimed BraytonHughes Design Studios, San Francisco ... property and the largest in Hawaii—received a complete re-envisioning. ...
(Date:7/24/2014)... HealthDay Reporter THURSDAY, July 24, 2014 (HealthDay News) -- ... according to a small study that asked boys what they really ... the ages of 14 and 16, researchers found that most said ... trust. Very few boasted about sexual conquests or saw sex as ... "In our culture, we have lots of assumptions about how guys ...
Breaking Medicine News(10 mins):Health News:A Comparison of Graft Techniques for the Alveolar Ridge Prior to Oral Implant 2Health News:A Comparison of Graft Techniques for the Alveolar Ridge Prior to Oral Implant 3Health News:Informed consent: False positives not a worry in lung cancer study 2Health News:Informed consent: False positives not a worry in lung cancer study 3Health News:BellasDress Helps Brides Get High End Wedding Dresses for Their Romantic Weddings 2Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 2Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 3Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 4Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 5Health News:Teenage Boys Want Intimacy, Not Just Sex, Survey Finds 2Health News:Teenage Boys Want Intimacy, Not Just Sex, Survey Finds 3
... By Steven Reinberg HealthDay Reporter , TUESDAY, ... called infective endocarditis, coupled with heart failure, heart valve surgery ... new study suggests. Infective endocarditis, an infection of ... valves, has been associated with a high risk of death. ...
... , TUESDAY, Nov. 22 (HealthDay News) -- ,Taking slightly ... the brand name Tylenol) over time can lead to an ... a new study. These "staggered overdoses" can occur when ... acetaminophen than they should, explained Dr. Kenneth Simpson, author of ...
... By Steven Reinberg HealthDay Reporter , TUESDAY, ... "energy" drinks skyrockets, so do related health problems, a ... almost 10 times more cases of reactions to beverages such ... to a new U.S. government report released Tuesday. More ...
... , TUESDAY, Nov. 22 (HealthDay News) -- Elderly black ... are much more likely to die in the hospital than ... risk of death was present even when black patients had ... researchers found. Diverticulitis occurs when small pouches in the ...
... discovered the novel protective role dendritic cells play in ... issue of journal Gastroenterology , shows dendritic cells ... dangerous swelling and inflammation of the pancreas gland. ... dendritic cells are needed in the pancreas for normal, ...
... News) --,College students tend to smoke when they are partying, ... are using social events and work as cues to remind ... an assistant professor of family and community medicine at the ... "This research is important for those working with college students ...
Cached Medicine News:Health News:Surgery May Boost Survival With Dangerous Heart Condition 2Health News:Surgery May Boost Survival With Dangerous Heart Condition 3Health News:Too Much Acetaminophen Over Time May Damage Liver 2Health News:ER Visits for Energy-Drink Ills Soar in U.S. 2Health News:ER Visits for Energy-Drink Ills Soar in U.S. 3Health News:More Blacks Die in Hospital After Diverticulitis Surgery 2Health News:Dendritic cells protect against acute pancreatitis 2Health News:Dendritic cells protect against acute pancreatitis 3Health News:College Students Smoke When They Party, Drink and Work 2
... (PxE) is a licensed 96 well PCR machine, ... for money thermal cycling. It is built ... in manufacturing and retains a high level of ... products in the range. The combination of ...
Custom programming of 3 hot blocks and 1 cold block, 30% reduction in cycling time, Unmatched well-to-well uniformity, No gradient feature...
... With Exceptional Performance The sleek ... might be the first things ... is designed for performance. With ... premium, its small footprint is ...
... The 96-Well GeneAmp PCR System 9700 ... and Aluminum Sample Blocks Modules. The aluminum ... of PCR reactions and cycle sequencing in ... This allows the 96-well 9700 system to ...
Medicine Products: